

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**Isoflavones and green kiwifruit:
A pilot study assessing the effects on bone turnover and
lipid profile in healthy postmenopausal New Zealand
women.**

A Thesis presented in partial fulfilment of the requirements for the degree of

Master of Science

in

Physiology

at Massey University, Palmerston North

New Zealand.

Catherine Middlemiss

2014

Statement of contribution

Professor MC Kruger – study conception, design and funding.

Mrs CL Booth – Human studies coordinator – ethics application, recruitment, coordination and execution of the study.

Ms C Middlemiss – Support in sample collection and processing, assistance with the DPD and ucOC assays, dietary analyses, and independent data collection, statistical analyses and interpretation.

Source of funding – This research was funded by New Zealand (Ministry of Business, Innovation and Employment) and Japan (Japanese Science and Technology Agency) for the Strategic Bilateral Agreement Program on Functional Foods.

Statement of originality

“I hereby declare that this thesis is my own word and that, to the best of my knowledge and belief, it contains no material previously published or written by another person nor material which a substantial extent has been accepted for the qualification of any other degree or diploma of a university or other institution of higher learning, except where due acknowledgement is made”.

Signed

Date

Abstract

Background: The reduction in estrogen synthesis during menopause heightens the risk of development of osteoporosis and cardiovascular disease in postmenopausal women. Isoflavone (daidzein and genistein) interventions in postmenopausal women have reduced bone loss, and improved the serum lipid profile, which may reduce the risk of fracture and incidence of cardiovascular disease. However, skeletal benefits are inconsistent across interventions. This is partly a result of population heterogeneity in enteric bacterial daidzein metabolism – only ~30% of Caucasian women produce equol, a daidzein metabolite. Equol is more bioactive than its precursor and equol producers have more consistently shown skeletal benefits from isoflavone supplementation. Few interventions have accounted for equol production in postmenopausal study populations. Additionally, there is limited knowledge on how prebiotic foods, such as green kiwifruit, modulate daidzein-metabolising bacteria and equol production in humans. This pilot study aimed to assess bone turnover in response to isoflavone supplementation, and to determine the proportion of equol producers in postmenopausal women.

Objectives: The main objective was to measure the effect of short-term daily isoflavone supplementation alone or with the addition of green kiwifruit on biochemical markers of bone resorption, urinary deoxypyridinoline, plasma cross-linked C-terminal telopeptide of type I collagen, and plasma undercarboxylated osteocalcin in postmenopausal Caucasian women. A secondary objective was to measure the effect of isoflavones and kiwifruit on serum lipid profile. Additionally, equol production was determined in this population and assessed as a main effect.

Methods: This randomised crossover pilot study recruited 33 healthy postmenopausal Caucasian women, 1-10 years postmenopausal, and randomly allocated participants to treatment group A (n=16) or B (n=17) for a 16-week intervention. There were two consecutive 6-week treatment periods with a 2-week lead-in period at intervention commencement and a 2-week washout period between treatments. These treatments prescribed either: (1) daily isoflavone supplementation (50 mg/day aglycone daidzein

and genistein) alone or (2) with two green kiwifruit. Group A and B completed both treatments in opposite order. At treatment baseline and endpoints the following were measured (four time points): bone markers, serum lipid profile and both serum and urinary daidzein and equol. The hormones, serum follicle stimulating hormone, estradiol and thyroid-stimulating hormone, were also measured at baseline and endpoint to monitor potential adverse effects of isoflavones.

Results: Equol producers made up 30% of this study population (equol producers n=10; non-equol producers n=30). Serum equol rose significantly in equol producers. Plasma undercarboxylated osteocalcin decreased by 15.5% after the kiwifruit and isoflavone treatment and increased by 10.8% after the isoflavone only treatment. There were no changes in plasma C-terminal telopeptide of type I collagen or urinary deoxypyridinoline. In non-equol producers high-density lipoprotein cholesterol declined by an average of 4.9% with each treatment; there was no change in serum high-density lipoprotein cholesterol in equol producers following isoflavone treatment alone, and an 8.3% increase in serum high-density lipoprotein cholesterol following the combined kiwifruit and isoflavone combined. There were no other changes to the lipid parameters or hormones.

Conclusions: An aglycone isoflavone dose of 50 mg/day did not reduce bone resorption in the postmenopausal women in this study. Kiwifruit consumption decreased plasma undercarboxylated osteocalcin levels possibly due to the vitamin K content of green kiwifruit; however, alternative bioactive components in kiwifruit may have modulated this effect. The isoflavone treatment inhibited a decline in serum high-density lipoprotein cholesterol in equol producers and had synergistic effect with kiwifruit, which increasing this parameter. Equol and the carotenoid lutein from green kiwifruit may potentially modulate systemic inflammation. Kiwifruit may have a prebiotic effect in equol producers as shown by the increase in log ratio of daidzein to equol, but this requires further study. This equol producer subgroup was too small to detect a change the markers of bone resorption. Larger long-term studies are required to delineate the skeletal and cardiovascular effects of isoflavones and equol production in postmenopausal women.

Acknowledgments

I would like to sincerely thank both my chief Supervisor Professor Marlina Kruger and co-supervisor Associate Professor Jane Coad for all their expertise, patience and feedback; you both are inspiring scientists. Many thanks to Mrs. Chris Booth for her coordination of the study in the Human Nutrition Unit and to Mrs. Marie-Tine Biersteker for her excellent phlebotomy skills. I would also like to personally thank the dedicated participants who made this study possible. Thank you to Dr Shinichi Katsumata and Gabrielle Plimmer for the analysis of bone markers (DPD and ucOC), and to Felicity Jackson for the analysis of urinary creatinine in the IFNHH laboratories. Thank you to Zespri® International Ltd. (Mt Maunganui, NZ) for providing the green kiwifruit for this study.

I owe great thanks to Professor Patrick Morel for his patient help with my statistical analysis. Dr. David Simcock, your advice, encouragement, and faith in my abilities have helped me to see this thesis through to the end; I am deeply grateful for your support.

To the zoology postgrad room: thanks for the many coffee breaks and interesting conversations and debates. To my flatmates, Chelsea, Alix, Jessy, Rose and Jerramiah: you have made the completion of my masters some unforgettable years! Chelsea, thank you for always offering me perspective; your wisdom has kept me grounded.

My family, Mum, Tim, Gen and Dad, I dedicate this work to you; your absolute pride and support for me in my academic endeavours has kept me going throughout the last few years. Mum, thank you for always being so interested in my work; I am truly lucky to have you care so much for my future.

"I'd rather have a mind opened by wonder than one closed by belief"

Albert Einstein

Table of contents

Statement of contribution	iii
Statement of originality	v
Abstract	vii
Acknowledgements	ix
Table of contents	xi
List of figures	xvi
List of tables	xvii
List of abbreviations	xviii
1 Chapter One – Introduction	1-4
1.1 Study background	1
1.2 Purpose of study	3
1.2.1 Study objectives	
1.2.1.1 Primary objective	3
1.2.1.2 Secondary objective	4
1.2.2 Study hypotheses.....	4
1.3 Layout of thesis	4
2 Chapter Two – Literature review	5-55
2.1 Bone composition	5
2.2 Bone metabolism	6
2.3 Osteogenic cells	7
2.3.1 Osteoclastogenesis and osteoclast function	7
2.3.2 Osteoblastogenesis and osteoblast function	10
2.3.3 The signal triad regulating osteogenic cross-talk	12
2.3.4 Osteocytes and mechanical loading	12
2.4 Factors affecting bone health	13
2.4.1 Physiological regulators	13
2.4.1.1 Vitamin D	14
2.4.1.2 Parathyroid hormone	16

2.4.1.3	Calcitonin	17
2.4.1.4	Estrogen	18
2.4.1.5	Local factors	18
2.4.2	Lifestyle factors	20
2.4.2.1	Physical activity	20
2.4.2.2	Nutrition	21
2.4.2.2.1	Calcium	21
2.4.2.2.2	Phosphate	22
2.4.2.2.3	Vitamin K	22
2.4.2.2.4	Magnesium	23
2.4.2.2.5	Vitamin C	23
2.5	Osteoporosis	24
2.5.1	Definition and causes of osteoporosis	24
2.5.1.1	Glucocorticoid excess	24
2.5.1.2	Aging	25
2.5.1.3	Sex steroid deficiency	25
2.5.2	Postmenopausal osteoporosis	25
2.5.2.1	Structural changes to bone in postmenopausal osteoporosis.....	26
2.5.2.2	Changes to bone metabolism in postmenopausal osteoporosis	27
2.6	Assessing bone health	28
2.6.1	Bone mineral density and bone turnover	28
2.6.2	Biochemical markers of bone resorption: CTx and DPD	29
2.6.3	Biochemical marker of bone health: ucOC	29
2.7	Treatment for postmenopausal osteoporosis	30
2.7.1	Phytoestrogens: specific effects on bone health and general effects on cardiovascular health.....	31
2.7.1.1	Phytoestrogens: bone turnover and bone density	31
2.7.1.2	Phytoestrogens: lipid metabolism and cardiovascular disease.....	31
2.7.2	Soy isoflavones and their metabolism	33

2.7.3	Daidzein and genistein: mechanisms of bone health modulation	35
2.7.3.1	<i>In vitro</i> studies	35
2.7.3.1.1	Estrogenic activity	35
2.7.3.1.2	Other mechanisms	36
2.7.3.2	Animal studies	37
2.7.3.3	Human studies	39
2.7.3.4	Discrepancies in human studies	41
2.8	The importance of equol	45
2.8.1	Equol benefits to bone	45
2.8.1.1	<i>In vitro</i> studies	45
2.8.1.2	Animal studies	45
2.8.1.3	Human studies	47
2.8.2	Factors influencing the equol producer phenotype in humans	50
2.8.2.1	Dietary factors	51
2.8.2.2	Green kiwifruit, equol production and bone health	52
2.9	Summary	55
3	Chapter Three – Methods	56-66
3.1	Intervention overview	56
3.2	Intervention design	56
3.2.1	Soy isoflavone supplement	57
3.2.2	Green kiwifruit	58
3.2.3	Dietary restrictions	58
3.3	Ethics approval and considerations	58
3.4	Participants	59
3.4.1	Eligibility criteria	59
3.4.1.1	Inclusion criteria	59
3.4.1.2	Exclusion criteria	60
3.4.2	Recruitment	60

3.4.3	Participants of this study	61
3.4.4	Sample size	61
3.4.5	Randomisation	61
3.5	Data collection	62
3.5.1	Anthropometric measurements	62
3.5.2	Measurement of bone mineral density	62
3.5.3	Dietary assessment	62
3.5.4	Blood and urine samples and biochemical analyses	63
3.5.4.1	Sample collection requirements	63
3.5.4.2	Blood sampling	63
3.5.4.3	Urine sampling	64
3.5.5	Biochemical analyses	64
3.5.5.1	Bone markers	64
3.5.5.2	Lipids and hormones	65
3.5.5.3	Isoflavones and vitamin D	65
3.6	Compliance	65
3.7	Statistical analysis	65
4	Chapter Four – Results	67-80
4.1	Baseline characteristics	67
4.2	Biochemical analyses	69
4.3	Bone markers	72
4.3.1	Serum ucOC	72
4.3.2	Serum CTx and urinary DPD	73
4.4	Serum lipid profile	74
4.4.1	Serum HDL-c	74
4.4.2	Serum TC, TAG, LCL-c and the ratio of TC to HDL-c	75
4.5	Equol production	76
4.5.1	Log ratio of daidzein to equol	76
4.5.2	Serum equol	78
4.6	Hormones: serum E2, FSH and TSH	79

List of figures

Figure 2.1	Illustration of osteoclast lineage specification. Image reproduced with permission from Crockett et al. (2011)	9
Figure 2.2	Illustration of osteoblast lineage specification. Image adapted and reproduced with permission from Crockett et al., (2011)	11
Figure 2.3	The molecular structures of soy isoflavones. Image reproduced with permission from Lye, Kuan, Ewe, Fung, & Liong (2009)	34
Figure 3.1	An illustration of the 16-week crossover intervention	57
Figure 4.1	Bar graph showing the mean percentage change in plasma ucOC	72
Figure 4.2	Bar graph showing the mean percentage change in plasma CTx	73
Figure 4.3	Bar graph showing the mean percentage change in urinary DPD	73
Figure 4.4	Bar graph showing the mean percentage change in serum HDL-c	75
Figure 4.5	Bar graph showing the mean change in the log ratio of urinary daidzein to equol	76
Figure 4.6	Bar graph showing the mean change in serum equol	77

List of tables

Table 2.1	A summary of some recent isoflavone interventions in post-menopausal women and the effect on BMD	43
Table 2.2	Green kiwifruit: selected micronutrient content and percentage contribution to RDI in NZ women (51-70 years)	53
Table 4.1	Baseline characteristics of groups A and B	68
Table 4.2	P values for the main treatment effects and interactions for the bone markers, lipid parameters, hormones and isoflavones	70
Table 4.3	The means change in bone markers, lipid parameters, hormones and isoflavones	71
Table 4.4	The mean percentage change in the bone markers	72
Table 4.5	The mean percentage change in serum HDL-c	74
Table 4.6	Significant three-way interactions between treatment, time and equol producer status	78
Table 4.7	Pearson Chi-Square table showing distribution of participants with E2 levels <37 and >37 pmol/L	79
Table 4.8	P values of the significant main effects	80
Table 5.1	Micronutrient intake of this study population and comparison national RDIs.....	84

Abbreviations

1,25(OH) ₂ D	Calcitriol
24,25(OH) ₂ D	Dihydroxycholecalciferol
25(OH)D	Calcidiol
AA	Arachidonic acid
AI	Adequate intake
B-ALP	Bone alkaline phosphatase
BMC	Bone mineral content
BMD	Bone mineral density
BMI	Body mass index
BMP	Bone morphogenetic protein
BRU	Bone resorptive unit
CaSR	Calcium sensing receptor
COX	Cyclooxygenase
CTx	Cross-linked C telopeptide of type 1 collagen
DBD	Vitamin D binding protein
DEXA	Dual-energy X-ray absorptiometry
DPD	Deoxypyridinoline
E2	Estradiol
ECM	Extracellular matrix
ER α / β	Estrogen receptor alpha/beta
FGF	Fibroblast growth factor
FOS	Fructooligosaccharide
FSD	Functional secretory domain
FSH	Follicle stimulating hormone
GC	Glucocorticoid
HDL-c	High-density lipoprotein cholesterol
HRT	Hormone replacement therapy
ID	Identification
IGF	Insulin-like growth factor
IL	Interleukin

LDL-c	Low-density lipoprotein cholesterol
LRP	Low density lipoprotein-related receptor
M-CSF	Monocyte colony stimulating factor
MCP	Monocyte chemoattractant protein
Mg	Magnesium
NHANES	National Health and Nutrition Examination Survey
NO	Nitric oxide
O-DMA	O-desmethylangolensin
OC	Osteocalcin
OPG	Osteoprotegerin
Ovx	Ovariectomised
PA	Physical activity
PBM	Peak bone mass
PGE	Prostaglandin
PPAR	Peroxisome proliferator-activated receptor
pQCT	Peripheral quantitative computed tomography
PTH	Parathyroid hormone
RANK	Receptor activator for nuclear factor $\kappa\beta$ factor
RANKL	Receptor activator for nuclear factor $\kappa\beta$ factor ligand
RB	Ruffled border
RCT	Randomised controlled trial
RDI	Recommended daily intake
SEM	Standard error of the mean
SD	Standard deviation
TAG	Triacylglycerol
TC	Total cholesterol
TC:HDL-c	Ratio of total cholesterol to high-density lipoprotein cholesterol
TGF β	Transforming growth factor beta
TNF- α	Tumour necrosis factor alpha
TSH	Thyroid stimulating hormone
ucOC	Undercarboxylated osteocalcin
Wnt	Wingless type

